Who's Left to Acquire in CDMO Biomanufacturing? A Select Few.
August 25, 2022
Tags:
In his M&A column in our Q2 issue, Nice Insight's Nigel Walker explores factors impacting demand for CDMO services, how they are changing the M&A market, and some CDMOs that might be on the block for acquisition.
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.
.svg)
